A study on behalf of the Acute Leukemia Working Party of the EBMT, presented by Prof. Spyridonidis Is 8- instead of 12-Gray sufficient for acute lymphoblastic ,leukemia patients transplanted in first complete remission? Total body irradiation (TBI) continues to be an important part...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z. Post-transplant cyclophosphamide (PTCY) is increasingly used for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLA-matched unrelated donor (MUD) as an alternative to the standard anti-thymocyte globulin...

Presenters: Dr Wendy Stock, Dr Scott Howard, Dr Stephen Hunger, Dr Dan Douer Participants: Prof. Spryridonidis See the on-demand webcast of ASH2021 titled “Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience” On ASH2021 symposium the treatment of adult patients with Acute Lymphoblastic Leukemia with pegaspargase was discussed, as well...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z. Patients with DLBCL primary refractory or relapsed ≤ 12 mo after first-line (1L) therapy may have poor outcomes with SOC, including salvage CT and ASCT, which underscores a...

Presenter: Stephen Kim (Manager QA Site Qualification) Participants: Dr Liga, Dr Triantafyllou, Christopoulou A., Sagiadinou E., Kefala D., Parastatidou S., Tzourtzou A., Maniati S. Την Τετάρτη 02 Φεβρουαρίου 2022 πραγματοποιήθηκε εκπαίδευση του προσωπικού που συμμετέχει στη Λευκαφαίρεση από την εταιρεία Kite Pharma. H εκπαίδευση...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A. Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less intense therapies are being used more often in AML, the dichotomy between...

Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas  Due to fast spreading of SARS-CoV-2 a panel of experts of EBMT recommends the following guidelines for transplant units, recipients, and donors of hematopoietic cells. These guidelines will be updated when new information is...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Christopoulou A., Sagiadinou E. Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible...

In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion,...

In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in...

The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. In this international, phase 3 trial, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy...

Oμιλητής: Καθ. Αλέξανδρος Σπυριδωνίδης, 21ο Πανελλήνιο Συνέδριο Μεταμοσχεύσεων

The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with...

Η Novartis Oncology συνεχίζοντας τη δέσμευσή της να συμβάλλει στην ιατρική εκπαίδευση και στην επιστημονική ενημέρωση των επαγγελματιών υγείας, θα θέλαμε να σας ενημερώσουμε ότι το Τμήμα Αιματολογίας της Novartis συνεχίζει θα παρέχει για τρίτη συνεχόμενη χρονιά στους επαγγελματίες υγείας τη δυνατότητα να παρακολουθήσουν μέσω διαδικτύου την εικονική συνάντηση Ειδικών με θέμα...

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

Transplantation in lower-risk myelodysplastic syndromes Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas ​

An analysis integrating ELN 2017, NPM1 MRD and KB scores to answer the question whether to transplant or not.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. Ιt was found that T cells of patients relapsing with AML after allo-HCT exhibited reduced glycolysis and interferon-γ production. Functional studies in multiple mouse models of leukemia showed that leukemia-derived lactic...